ArticleCOVID2025
Mortality and Predictors of Mortality Among COVID-19 Patients in Kiambu County, Kenya.
Article in COVID, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
SARS-CoV-2 continues to circulate with new variants of uncertain transmissibility and virulence arising over time and resulting in varying morbidity and mortality between and within countries. This study aimed to identify the predictors of mortality among hospitalized COVID-19 patients across the first five waves of the pandemic. We conducted a retrospective cohort study at Tigoni Level 4 Hospital in Kenya. The study included patients admitted between June 2020 to August 2022 who tested positive for SARS-CoV-2. Sociodemographic and clinical data were abstracted from patient records at the time of admission and throughout their hospital stay. We employed Cox proportional hazard regression analysis to estimate the time to event (discharge or death) and identify predictors of mortality. Both time-varying and non-time-varying covariates were included in the models. A total of 1985 patients were admitted, of whom 557 (28%) died. The median hospital stay was 4 (1.0-8.0) days and 9 (5.0-13.0) days for patients who died and those who were discharged alive, respectively. Compared to patients admitted during wave 1, those admitted during the subsequent waves had high risk of death estimated at adjusted HR: 1.66 (95% CI 1.2, 2.54), 5.17 (95% CI 3.55, 7.53), 2.62 (95% CI 1.87, 3.67), and 2.17 (95% CI 1.51, 3.11) for waves 2, 3, 4, and 5, respectively. A proportion of patients presented with persistent chest pain, cough, and hypoxia and continued oxygen therapy for more than two months. In addition, patients who had persistent fever, hypoxia, cough, and fatigue had a significant mortality risk (adjusted HR: 3.00; 95% CI: 1.81-4.98; HR: 1.97; 95% CI: 1.73-2.26; HR: 1.47; 95% CI: 1.24-1.75; HR: 1.64; 95% CI: 1.05-2.54). Conversely, patients who had low oxygen saturation and received oxygen at admission had a 76% (HR: 0.24; 95% CI: 0.13-0.42) reduction in mortality risk and in addition patients whose treatment was altered had a 49% reduction in mortality risk (HR: 0.51; CI: 0.45-0.58). Our study highlights the benefits of oxygen therapy on the outcome of COVID-19 patients and justifies the need to increase investments in oxygen especially in low-and-middle-income countries. It also confirms the need to analyze the pandemic by the different waves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.